Bank of America Corp DE Raises Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of America Corp DE increased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 59.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 766,224 shares of the biotechnology company's stock after buying an additional 286,569 shares during the quarter. Bank of America Corp DE owned about 0.32% of ADMA Biologics worth $13,141,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in ADMA Biologics by 1.3% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company's stock valued at $865,000 after acquiring an additional 645 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in ADMA Biologics by 1.3% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company's stock valued at $954,000 after acquiring an additional 700 shares in the last quarter. Summit Investment Advisors Inc. raised its position in ADMA Biologics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company's stock valued at $404,000 after acquiring an additional 746 shares in the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of ADMA Biologics by 2.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company's stock worth $614,000 after buying an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System raised its position in shares of ADMA Biologics by 1.1% during the fourth quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company's stock valued at $1,365,000 after buying an additional 897 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ADMA. Raymond James lifted their price target on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a research note on Friday, May 9th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Price Performance

NASDAQ ADMA traded up $0.02 during trading hours on Wednesday, reaching $19.91. 353,456 shares of the stock traded hands, compared to its average volume of 3,131,083. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a 1 year low of $9.35 and a 1 year high of $25.67. The stock has a 50 day simple moving average of $20.67 and a two-hundred day simple moving average of $18.90. The company has a market cap of $4.75 billion, a price-to-earnings ratio of 71.10 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). The company had revenue of $114.80 million during the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.08 earnings per share. On average, analysts predict that ADMA Biologics, Inc. will post 0.51 EPS for the current fiscal year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 7,779 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $20.32, for a total value of $158,069.28. Following the completion of the transaction, the director now directly owns 114,830 shares of the company's stock, valued at approximately $2,333,345.60. The trade was a 6.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.70% of the stock is owned by insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.